Geopolitical Analyst, Steno Research, Steno Research

Mikkel Rosenvold

Geopolitical Analyst, Steno Research

Macro and Geopolitical Research House

Steno Research

Steno Research is a new macro and geopolitical research house. We are based out of Copenhagen, Denmark, but have an international team and a strong network of sources and partners around the world. The team is lead by Andreas Steno, previous global head of strategy at Nordea Bank, and Mikkel Rosenvold, former chief consultant in the Danish Ministry of Finance.

Cross Asset Strategy

<ul><li>We cover the Trump assassination attempt in other spaces, so in this we’ll focus on the political fallout and touch upon other relevant topics, including the Chinese Policy Plenary.</li><li>Firstly some thought on Trump picking J.D. Vance as his running mate.</li><li>As a staunch Trump supporter, Vance represents a more grassroots, anti-establishment figure compared to others like Nikki Haley.</li></ul>

We cover the Trump assassination attempt in other spaces, so in this we’ll focus on the political fallout and touch upon other relevant topics, including the Chinese Policy Plenary.Firstly some thought on Trump picking J.D. Vance as his running mate.As a staunch Trump supporter, Vance represents a more grassroots, anti-establishment figure compared to others like Nikki Haley.

Great Game – Trump: Election or Coronation?

Founder & Head of Research, Fortress Hill Advisors

Alex Ng

Founder & Head of Research

Fortress Hill Advisors

Founded in Hong Kong in 2019, Fortress Hill Advisor seeks to provide premium economic and financial researches.

Premium Economic & Investment Research

Macroeconomics

<ul>
<li>In a recent forum, Chinese Premier Li Qiang is confident that Chinese economy was stagnant simply because of COVID. Now that COVID has gone, Chinese economy will eventually heal itself.</li>
<li>We believe rather Chinese economy will still be bumpy after COVID, with three major arrows against Chinese Economy, namely property sector slump, local government debt, and weak private sector.</li>
<li>Instead of the "self recovery" view of the economy proposed by Li, we believe government should more actively roll out fiscal and monetary stimulus.</li>
</ul>


In a recent forum, Chinese Premier Li Qiang is confident that Chinese economy was stagnant simply because of COVID. Now that COVID has gone, Chinese economy will eventually heal itself.
We believe rather Chinese economy will still be bumpy after COVID, with three major arrows against Chinese Economy, namely property sector slump, local government debt, and weak private sector.
Instead of the "self recovery" view of the economy proposed by Li, we believe government should more actively roll out fiscal and monetary stimulus.


Response to Premier Li: Post COVID Chinese Economy

Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Virios Therapeutics, Inc. operates as a biotechnology company. The Company develops novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Virios Therapeutics serves patients in the United States.

<ul><li>On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update.</li><li>The company announced that the Phase 2 clinical trial of IMC-2 (valacycovir+celecoxib) has reached 50% enrollment and we anticipate topline results from the trial in the second half of 2024.</li><li>Earlier this year, Virios announced that it had reached alignment with the U.S. Food and Drug Administration (FDA) that would allow the company to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint in future trials of IMC-2 for the treatment of Long COVID. The results of the ongoing Phase 2 trial of IMC-2 will help to guide the final design of a Phase 2b trial.</li></ul>

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update.The company announced that the Phase 2 clinical trial of IMC-2 (valacycovir+celecoxib) has reached 50% enrollment and we anticipate topline results from the trial in the second half of 2024.Earlier this year, Virios announced that it had reached alignment with the U.S. Food and Drug Administration (FDA) that would allow the company to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint in future trials of IMC-2 for the treatment of Long COVID. The results of the ongoing Phase 2 trial of IMC-2 will help to guide the final design of a Phase 2b trial.

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24 

Looking for No-Brainers in the Micro-Cap Space, The Mikro Kap

The Mikro Kap

Looking for No-Brainers in the Micro-Cap Space

Private investor from Croatia focused on finding no-brainer opportunities in the global micro-cap space

Articore Group Limited owns and operates global online marketplaces. The Company offers products such as apparel, art prints, stationery, housewares, bags and wall art, greeting cards, laptop skins, stickers, throw pillows, spiral notebooks, mugs, and postcards. Articore Group serves customers worldwide.

<ul><li>Redbubble was a bubble. On the wings of pandemic mania, the stock price increased 13 times from March 2020 to January 2021.</li><li>Reaching a 1.9B market cap. Today, the situation looks quite different.</li><li>The stock is down 93% from its highs of 7 AUD and currently sits at 0.</li></ul>

Redbubble was a bubble. On the wings of pandemic mania, the stock price increased 13 times from March 2020 to January 2021.Reaching a 1.9B market cap. Today, the situation looks quite different.The stock is down 93% from its highs of 7 AUD and currently sits at 0.

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Tokyo Metro Co., Ltd. offers passenger service. The Company mainly operates passenger rail transportation business. Tokyo Metro also offers station stores operation, real estate, and  advertising services.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/tokyo-metro" target="_blank" data-smartkarma-citation="entities:40930:1" rel="noopener">Tokyo Metro (TKYMETRO JP)</a>’s shareholders, the Japanese and Tokyo Metropolitan Governments, could look to raise up to US$2bn by selling half of their stake via an IPO.</li>
<li>Tokyo Metro is one of the two metro network operators in the Tokyo region. It operates nine subway lines.</li>
<li>In this note, we take an early look at the possible listing.</li>
</ul>



Tokyo Metro (TKYMETRO JP)’s shareholders, the Japanese and Tokyo Metropolitan Governments, could look to raise up to US$2bn by selling half of their stake via an IPO.
Tokyo Metro is one of the two metro network operators in the Tokyo region. It operates nine subway lines.
In this note, we take an early look at the possible listing.


Tokyo Metro IPO Early Look - Could Raise Around US$2bn While Still Recovering from COVID

On the impact of Coronavirus and COVID-19